Read this module from Nina Shah, MD, to learn more about how BCMA-targeted agents work in multiple myeloma and how you can use these agents in clinical practice to improve patient outcomes.
Download these slides with the most recent data on BCMA-targeted agents in multiple myeloma, including information on mechanism of action, clinical trial data, and implications for clinical practice.
Learn how experts incorporate BCMA-directed therapies for multiple myeloma into their practice.
We’ve heard a great deal about BCMA-targeted CAR T-cell therapy and antibody–drug conjugates for R/R MM. In this commentary, Dr Sagar Lonial discusses how BCMA-targeted bispecific therapies will fit in to the treatment landscape.
Download this resource developed to serve as a helpful guide for healthcare professionals on the use of BCMA-targeted therapies for treatment of multiple myeloma.
Contact Clinical Care Options
For customer support please email: customersupport@cealliance.com
Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.